Embarc

Soaring Eagle Acquisition Corp.

Merged
CIK: 1830214•Ticker: SRNG•Merged Ticker: DNA
Successfully merged with Ginkgo Bioworks, Inc. • Now trading as DNA

SPAC Overview

$1.7B
IPO Size
$37.6K
Trust (as of 2021-06-30)
Completed
Current Status
2021
IPO Year

Timeline Progress

About

Soaring Eagle Acquisition Corp. is a blank-check company formed to merge with, acquire, or combine with one or more businesses that have not yet been selected. It is a generalist, with no industry, sector, or geographic limitation on its search.

Embarc dashboard

What the sponsor registered, what the deal actually priced at, and every 8-K that moved it — unit structure, sponsor promote, and the dated lifecycle events, each linked to its filing.

  • Unit structure as registered and as priced — price, warrant coverage, rights, trust per unit
  • Sponsor promote: founder shares and percentage, private-placement warrants, trust deposit
  • The full 8-K lifecycle timeline, each event linked to its filing
  • Price history across the unit, share and warrant tickers
  • Follow it, and see it change on your watchlist
Open in the dashboard

SPAC Team

Sponsors

Eagle Equity Partners

Leadership

Harry E. Sloan
Chairman of the Board of Directors, Chief Executive Officer, Director, Director Nominee
Marijn E. Dekkers
Chairman of the Board of Directors, Director, Director Nominee
Jason R. Kelly
Chief Executive Officer, Director, Director Nominee, Founder
Eli Baker
Chief Financial Officer, President, Secretary
Reshma P. Shetty
Chief Operating Officer, Director, Director Nominee, Founder, President, President and Chief Operating Officer
Mark E. Dmytruk
Chief Financial Officer
Kathy Hopinkah Hannan
Director
Arie S. Belldegrun M.D.
Director, Director Nominee
Christian O. Henry
Director, Director Nominee
Dennis A. Miller
Director, Director Nominee
Isaac Lee
Director Nominee
Joshua A. Kazam
Director, Director Nominee
Laurence E. Paul
Director, Director Nominee
Reshma Kewalramani
Director, Director Nominee
Scott M. Delman
Director, Director Nominee
Shyam Sankar
Director, Director Nominee
Alan G. Mnuchin
Beneficial owner
Timothy Leiweke
Beneficial owner
Austin Che
Bartholomew Canton
Evan Lodes
Thomas Knight

Underwriters

Goldman Sachs

Extended Team Information

The team is led by Harry E. Sloan and Eli Baker, with founding investor Jeff Sagansky. They have extensive experience sponsoring SPACs and completing business combinations, including Flying Eagle/Skillz, Diamond Eagle/DraftKings and SBTech, Platinum Eagle/Target Hospitality, and Double Eagle/WillScot; their experience spans media, entertainment, gaming, and other sectors.

Stock Performance

DNA
Trading Symbol
First Trade
April 19, 2021
$10.61
At Merger
September 17, 2021
$12.18
+15%
6 Months Post-Merger
March 18, 2022
$3.05
-75%
1 Year Post-Merger
September 20, 2022
$2.94
-76%
2 Years Post-Merger
September 20, 2023
$1.83
-85%
Current Price
October 1, 2026
$12.50
+18%

Key Information

IPO Date
February 25, 2021
Total Redemptions
$867M
PIPE
$760M
State of Incorporation
DE
SIC
6770
Completion Date
September 15, 2021
Merger Target
Ginkgo Bioworks, Inc.
SPAC Ticker
SRNG
Merged Ticker
DNA

External Resources

SEC Filings
View Detailed Analysis